Axonics Modulation Technologies, Inc.
AXNX US05465P1012
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 14% | 7% | 4% | 18% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Snyderman Nancy Lynn Md O |
71.00 USD |
14,944 Sold |
1,061,024 USD |
15/11/2024 | 15/11/2024 |
| Ford Alfred J Jr CCO |
71.00 USD |
43,450 Sold |
3,084,950 USD |
15/11/2024 | 15/11/2024 |
| Kiernan Jane E O |
71.00 USD |
19,861 Sold |
1,410,131 USD |
15/11/2024 | 15/11/2024 |
| Ford Alfred J Jr CCO |
71.00 USD |
43,450 Sold |
3,084,950 USD |
15/11/2024 | 15/11/2024 |
| Lopez Esteban O |
71.00 USD |
6,600 Sold |
468,600 USD |
15/11/2024 | 15/11/2024 |
| Noblett Karen CMO |
71.00 USD |
34,428 Sold |
2,444,388 USD |
15/11/2024 | 15/11/2024 |
| Demski David M O |
71.00 USD |
9,542 Sold |
677,482 USD |
15/11/2024 | 15/11/2024 |
| Keese Kari Leigh CFO |
71.00 USD |
40,362 Sold |
2,865,702 USD |
15/11/2024 | 15/11/2024 |
| Carrel Michael H O |
71.00 USD |
17,861 Sold |
1,268,131 USD |
15/11/2024 | 15/11/2024 |
| Cohen Raymond W CEO |
71.00 USD |
292,731 Sold |
20,783,901 USD |
15/11/2024 | 15/11/2024 |